CN Stock MarketDetailed Quotes

002019 Yifan Pharmaceutical

Watchlist
  • 11.69
  • +0.42+3.73%
Market Closed Apr 29 15:00 CST
14.22BMarket Cap36.19P/E (TTM)

About Yifan Pharmaceutical Company

The company is an innovative R&D and manufacturing enterprise focusing on the field of medicine and health. The company is committed to combining classic discoveries with classic innovations to scientifically verify possible solutions and contribute updated expertise to the global medical and health industry. The company is mainly engaged in R&D, production, sales and drug promotion services for pharmaceutical products, APIs and polymer materials. The company's main products are ibergestine alpha injections, recombinant human insulin injections, recombinant human growth hormone for injection, capecitabine tablets, dingan crosslinked sodium hyaluronate injections, lactulose oral solution, ganciclovir hydrochloride tablets, vincristine sulfate injections, presofar injections, clofarabine injections, norepinephrine bitartrate injections, emestine fumarate sustained-release capsules, miastine fumarate nasal spray, concentrated solution for injections Triprorelin acetate, pediatric qingiao granules, compound silver flower detoxifying granules, maqin cough relief granules, dehumidifying and itchy ointment, skin sensitive relief capsules, Anti-itch scar softening cream, gynecologic lotion, compound Huangdai tablets, vitamin B5, provitamin B5, etc. Corporate honors include one of the new pharmaceutical products being developed by the company receiving the second prize of the National Science and Technology Progress Award.

Company Profile

Short Name-A亿帆医药
Symbol-A002019
Company NameYifan Pharmaceutical Co., Ltd
Listing DateJul 13, 2004
Issue Price12.57
Shares Offered15.00M share(s)
FoundedNov 10, 2000
Listed ExchangeSZ Stock Exchange
Legal Representativexianfeng cheng
General Managerxianfeng cheng
Secretarydeqi feng
Accounting FirmLixin Certified Public Accountants (Special General Partnership)
Securities Representativelei li
Legal CounselAnhui Tianhe Law Firm
Employees68
Phone0551-62672019
Office AddressNo. 50, Qinshan, Jincheng Street, Lin'an District, Hangzhou, Zhejiang
Zip Code311300
Registered AddressLin'an Economic Development Zone, Hangzhou, Zhejiang
Fax0551-66100530
Emaildsh@xinfupharm.com
Business License330000000007443
BusinessR&D and sales of food additives, feed additives, polymer materials (excluding dangerous goods and ready-to-manufacture drugs), pharmaceutical intermediates, sales of packaging materials, mechanical equipment and accessories, research and development of biotechnology and pharmaceuticals, technology development and transfer, technical consulting and services, and operation of import and export business. (Projects requiring approval according to law can only carry out business activities after approval by relevant departments).

Company Executives

  • Name
  • Position
  • Salary
  • xianfeng cheng
  • Chairman, Directors, President, Chairman of the Strategy Committee, Member of the Remuneration and Assessment Committee, Nomination Committee Members
  • 624.00K
  • deqi feng
  • Directors, Board Secretary, VP
  • 480.00K
  • yiqun ye
  • Directors
  • 480.00K
  • benyu zhou
  • Directors, Audit Committee Member, Strategy Committee Member
  • 480.00K
  • xing lin
  • Directors, VP
  • 562.60K
  • GENHONG CHENG
  • Independent Directors, Member of the Remuneration and Assessment Committee, Chairman of the Nomination Committee, Strategy Committee Member
  • 100.00K
  • hongquan liu
  • Independent Directors, Audit Committee Member, Chairman of the Remuneration and Assessment Committee, Strategy Committee Member
  • 100.00K
  • yuhong ceng
  • Independent Directors, Audit Committee Convener, Nomination Committee Members, Strategy Committee Member
  • --
  • lei li
  • Securities Affairs Representative
  • --
  • guohan xu
  • Chairman of the Supervisory Board, Auditors
  • 480.00K
  • lianchun zhang
  • Auditors
  • 480.00K
  • ximing li
  • VP
  • 2.94M
  • yuhong geng
  • VP
  • 1.91M
  • dawei zhang
  • Chief Financial Officer
  • 430.00K
  • chunyan huo
  • Director of Audit
  • --
  • jun wang
  • Employee Supervisors
  • 478.40K

Market Insights

Discussing

2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More